Glimepiride increases pancreatic release of insulin from functioning beta cells and, with continued use, may also increase peripheral tissue sensitivity to insulin. The exact mechanism for these effects is not well understood.
Glipizide may be of benefit in treating cats with type II diabetes if they have a population of functioning beta cells. It has been suggested that there are two situations when glipizide can be recommended, 1) If an owner refuses to consider using insulin usually due to a fear of needles, and 2) the cat appears to be relatively well controlled on quite small doses of insulin and the owner would strongly prefer to no longer give insulin (Feldman 2005b). While glipizide potentially could be useful in treating canine patients with type II or III diabetes, however, by the time dogs present with hyperglycemia, they are absolutely or relatively insulinopenic and glipizide would unlikely be effective.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
必須先確認動物物種、糖尿病診斷、酮症狀態、共病、目前降血糖治療與可執行的監測計畫。 任何使用都必須由獸醫師逐案選擇精確產品並處理低血糖、肝腎疾病與額外暴露風險。 健康貓的單次實驗不能轉成糖尿病貓療程，也不能轉成犬用資料。 在完整獸醫臨床契約與主審批准前，系統不得計算、開立、輸出或自動配對。
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。
9 hours